Stocks · News reference
Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a ---- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.